Eftilagimod alpha

N/A

Report date: 2026/05/02 20:00:18
First In Class

Base Information

Drug NameEftilagimod alpha
Drug Alias NameImmuFact IMP321LAG-3-Ig-fusion-proteinEftiEftilagimod alfahLAG-3Ig +[11] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionAntigen-presenting cells stimulantsHistocompatibility antigens class II stimulants
TargetsAntigen-presenting cellsHistocompatibility antigens class II
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursHR-positive breast cancer +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[32] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesImmutep Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesDr. Reddy’S Laboratories SaGeorge Washington University (The)Maria Sklodowska-Curie National Research Institute of Oncology +[9] 
Inactive CompaniesWashington University School Of MedicineCliniques Universitaires Saint-Luc A.S.B.L.Immutep Australia Pty Ltd
Active IndicationsSolid tumoursHR-positive breast cancerCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsMetastatic breast cancerPancreatic NeoplasmsMelanoma

Other Information

ATC CodeN/A
Related LinksWikipedia